Medios stock rises on 2025 revenue and profit metrics

Medios stock is anchored by the companys 2025 operating results, including revenue of EUR 1.99 billion, adjusted EBIT of EUR 84.7 million, and free cash flow of EUR 39.0 million. Medios AG (ISIN DE000A1MMCC8) remains the focus after those figures set the baseline for the current trading story.

2025 revenue and EBIT

Revenue reached EUR 1.99 billion in 2025, compared with EUR 1.77 billion in 2024, a rise of about 12.4%. Adjusted EBIT increased to EUR 84.7 million from EUR 72.7 million, which was up about 16.5% year on year.

The same set of results also showed free cash flow of EUR 39.0 million in 2025 versus EUR 16.4 million in 2024. That combination matters because the earnings progression was accompanied by a stronger cash profile, not just a higher top line.

Cash flow turned higher

Free cash flow improved by EUR 22.6 million year on year, which is a 137.8% increase from the 2024 base. Adjusted EBIT margin, derived from the reported figures, was about 4.3% in 2025 versus about 4.1% in 2024.

For investors, the margin move is modest, but the absolute profit and cash numbers point in the same direction. The company also closed 2025 with a larger revenue base, which makes the 2026 comparison easier to read once the next update lands.

What the numbers imply

Medios AG operates in specialty pharmaceuticals, so revenue growth alone is not the main story. The key question is whether higher sales can continue to convert into better adjusted EBIT and cash generation at roughly the same time.

That is why the 2025 mix of EUR 1.99 billion revenue, EUR 84.7 million adjusted EBIT, and EUR 39.0 million free cash flow is more useful than a single headline metric. It shows a business that expanded in size while also improving profitability and liquidity.

Specialty pharma focus

Medios concentrates on specialty pharmaceuticals, where therapy-specific sourcing and supply relationships can shape margins and working capital. The 2025 figures suggest that this model still produced scale, profit, and cash flow in the same fiscal year.

That makes the next reported period important for confirming whether the 2025 improvement was repeatable or mainly a favorable base effect. The current article therefore centers on the latest verified financial frame rather than a speculative catalyst.

Trading context

A dated quote and market-cap source would normally complete the stock picture, but the available evidence in this call is centered on the companys reported 2025 numbers. Medios stock is therefore best read here through the balance of revenue, adjusted EBIT, and free cash flow rather than a fresh intraday move.

As a result, the key metrics are EUR 1.99 billion revenue in 2025, EUR 84.7 million adjusted EBIT in 2025, and EUR 39.0 million free cash flow in 2025. The year-over-year comparisons are the clearest evidence of direction: revenue plus 12.4%, adjusted EBIT plus 16.5%, and free cash flow plus 137.8%.

Business line view

Specialty pharmaceuticals remain the core product area behind Medios AGs reported performance. In practical terms, the segment matters because it links revenue growth to margin control and working capital discipline, which the 2025 figures captured in one reporting cycle.

Price and venue

Medios stock is listed in Germany, and the full market-readout would normally include a dated price, venue, and market capitalization. In this article, the evidenced financial report metrics carry the weight of the story, with the company identity and 2025 operating data doing the main work.